Plain-English translation of NCT06163820 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a medication called , when combined with two standard immunotherapy drugs and a targeted form of radiation therapy, can safely treat melanoma that has spread to the brain and is causing symptoms. has shown promise in helping reduce side effects and may work together with the immunotherapy to fight the cancer more effectively.
Patients with melanoma that has spread to the brain typically have poorer outcomes than those with melanoma elsewhere in the body. While standard immunotherapy exists, doctors are looking for ways to improve results by adding this medication, which may help reduce brain swelling and potentially boost the immune system's ability to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication through an IV infusion starting one week before your immunotherapy begins, then continue every 3 weeks for four cycles alongside the immunotherapy drugs. At the same time or shortly after, you will receive focused radiation therapy to your brain tumors over either 3 or 5 treatment sessions. After the initial 4-cycle phase, you may continue on one of the immunotherapy drugs alone. You'll have regular visits to the hospital or clinic for infusions, monitoring, and imaging scans to check how you're responding to treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Australia
Phase
Safety & dosing / Early efficacy
Sponsor
Melanoma and Skin Cancer Trials Limited
Enrollment target
~46 participants
Started
May 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Katja Loewe
Monash University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.